Biogen Receives European Commission Approval for Qalsody® (Tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.